Novel hydroxyl dendrimer therapeutics
Location: United States, California, Redwood City
Employees: 11-50
Total raised: $119M
Investors 4
| Date | Name | Website |
| - | Deep Ventu... | deepventur... |
| - | Helios Cap... | helioscapi... |
| - | EcoR1 Capi... | ecor1cap.c... |
| 03.02.2021 | Plum Alley... | plumalley.... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 14.01.2025 | Series B | $50M | - |
| 27.04.2022 | Series B | $69M | - |
Mentions in press and media 4
| Date | Title | Description |
| 14.01.2025 | Ashvattha Therapeutics Raises $50M in Series B Extension Funding | Ashvattha Therapeutics, a Redwood City, CA-based clinical-stage company advancing a new class of nanomedicine therapeutics, announced additional financing as an extension of its Series B of up to $50M. The round was led by Tribe Capital and... |
| 02.05.2022 | What to know about Elon Musk’s $12.5 billion margin loan | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox. Big deals always pose risk. This one is different. Elon Musk, who submitted the letter to buy Twi... |
| 28.04.2022 | Ashvattha Therapeutics Closes $69M in Series B | REDWOOD CITY, CA, Ashvattha Therapeutics, a clinical stage company developing novel hydroxyl dendrimer therapeutics, has secured $69 million in a Series B round. >> Click here for more funding data on Ashvattha Therapeutics >&g... |
| 27.04.2022 | Ashvattha Therapeutics Announces $69 Million in Series B Financing and up to $45M Exclusive License Agreement with Huadong to Advance Hydroxyl Dendrimer-Based Precision Medicines | – Series B Financing led by Huadong Medicine Investment Holding Co., Ltd, with participation from Natural Capital Investment Fund, Plum Alley Investments and Tribe Capital – – Exclusive product licensing agreement grants Huadong development... |